Breast Reduction Vertical Incision in Surrey Canada
Breast reduction is an operation that is usually considered a reconstructive procedure and is many times covered by insurance plans. The surgery is performed to make the breasts smaller, as well as lift the breasts to a more youthful position. The purpose of the surgery is to alleviate back and neck pain as well as to aid in hygiene in the folds underneath the breasts.
Marks are made on the skin according to the type of reduction planned by the patient and the surgeon. This is usually performed before the patient is taken back to the operating room with the patient in a sitting or standing position.
With the patient now asleep, incisions are made around the predetermined marks on the breasts.
The breast tissue is removed with an electro cautery instrument that cauterizes bleeding vessels while it removes the breast tissue. This helps reduce the amount of blood that is lost during the operation.
The incisions are closed with sutures.
The patient is placed in a compression garment or bra. Compression garments are an important part of the recovery process. The garment provides support, comfort and helps to minimize swelling. The patient is usually wearing a bra or some type of supportive garment at all times, except when showering. Healing time is approximately three months. Scarring is variable and often depends on the patient's ability to heal.
More Surrey info...
Surrey By bus
Metrobus and Arriva operate in the Surrey area.
-
Plastic Surgery News...
- Scientists at the University of Manchester have found links between many types of childhood cancer and increased breast cancer risk in the mother. Although a previous study found high risk of breast cancer in mothers of children with soft tissue sarcomas, breast cancer risks in mothers of other childhood cancers remain largely unknown and the reasons for the links are not fully understood.
- GlaxoSmithKline plc announced that once-daily Avamys?(fluticasone furoate) nasal spray has been granted marketing authorisation by the European Commission for all 27 European member states, for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and older) and children (6 - 11 years).